Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ross Clevens

Plastic Surgery Within the Head and Neck Melbourne, FL Medical Doctor

NPI 1538140231 CMS profile 160550

707 W Eau Gallie Blvd, Melbourne, FL 32935

Open in the dashboard

General payments

$207,739

254 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ross Clevens of Melbourne, FL is reported in the CMS Open Payments database as having received $207,739 across 254 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Plastic Surgery Within the Head and Neck profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $334 16
2024 General $33,912 45
2023 General $68,532 36
2022 General $74,520 43
2021 General $27,616 41
2020 General $520 31
2019 General $2,305 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ross Clevens
  • Plastic Surgery Within the Head and Neck median
  • Middle half of Plastic Surgery Within the Head and Neck
  • National median

In program year 2025, general payments to Ross Clevens were reported at $334. Among 103 Plastic Surgery Within the Head and Neck profiles paid that year, the median was $300 and the middle half received between $115 and $580.

Show as a table
Year Ross Clevens Plastic Surgery Within the Head and Neck median Middle half National median
2019 $2,305 $270 $76–$780 $163
2020 $520 $172 $52–$421 $114
2021 $27,616 $227 $64–$753 $132
2022 $74,520 $338 $112–$800 $149
2023 $68,532 $303 $89–$723 $160
2024 $33,912 $289 $115–$714 $164
2025 $334 $300 $115–$580 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $102,791 123 payments
  2. AbbVie, Inc. $102,203 94 payments
  3. Merz North America, Inc. $2,178 17 payments
  4. Galderma Laboratories, L.P. $413 17 payments
  5. Zimmer Biomet Holdings, Inc. $123 1 payment
  6. Pacira Pharmaceuticals Incorporated $19 1 payment
  7. Pfizer Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $197,792 22 payments
  2. Food and Beverage $7,197 231 payments
  3. Consulting Fee $2,750 1 payment
Products named General payments · program years 2019–2025
  1. ASCLERA $1,636 16 payments
  2. Xeomin $1,636 16 payments
  3. BOTOX $1,215 30 payments
  4. BOTOX COSMETIC $476 29 payments
  5. Omni Max $123 1 payment
  6. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $59 3 payments
  7. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $56 3 payments
  8. NATRELLE $39 2 payments
  9. Exparel $19 1 payment
  10. DYSPORT $15 1 payment
  11. Other $49 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

201

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$2,073

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

32.8%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 23 $1,025
Valacyclovir Valacyclovir Hcl Brand 43 $464
Cephalexin Generic 69 $237
Cefadroxil Generic 24 $213
Doxycycline Hyclate Generic 16 $82
Promethazine Hcl Generic 26 $52

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$348,501

Of which drugs: $16

Medicare patients

304

Average age 75

Services billed

2,204

164 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 47%
Ischemic heart disease 25%
Diabetes 22%
Chronic kidney disease 22%
Atrial fibrillation 18%
Cancer 18%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 22 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $305
$305 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $19
$19 — —
DYSPORT
  • Galderma Laboratories, L.P. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

254 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery Within the Head and Neck in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record